# Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Study · id `cardio:ct-nct02239120` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02239120](<https://clinicaltrials.gov/study/NCT02239120>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02239120

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5390 participants.

## Technical summary

Registry record NCT02239120. Randomized; double masking; primary purpose prevention. Start 2014-11-27 (actual); primary completion 2018-08-14 (actual). Results posted on 2019-09-06.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 5390 participants (enrolled count; ClinicalTrials.gov record NCT02239120, source copy `cardio:ctgov-nct02239120-2019-09-06`, retrieved 2026-10-26)
- Started: 2014-11-27 (actual) (ClinicalTrials.gov record NCT02239120, source copy `cardio:ctgov-nct02239120-2019-09-06`, retrieved 2026-10-26)
- Primary completion: 2018-08-14 (actual) (ClinicalTrials.gov record NCT02239120, source copy `cardio:ctgov-nct02239120-2019-09-06`, retrieved 2026-10-26)
- Completion: 2018-08-14 (actual) (ClinicalTrials.gov record NCT02239120, source copy `cardio:ctgov-nct02239120-2019-09-06`, retrieved 2026-10-26)
- Results first posted: 2019-09-06 (ClinicalTrials.gov record NCT02239120, source copy `cardio:ctgov-nct02239120-2019-09-06`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Croatia; Czechia; Estonia; France; Germany; Greece; Hong Kong SAR China; Hungary; India; Israel; Italy; Japan; Malaysia; Mexico; New Zealand; Peru; Poland; Portugal; Russia; Serbia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; Ukraine (ClinicalTrials.gov record NCT02239120, source copy `cardio:ctgov-nct02239120-2019-09-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02239120-2019-09-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
- Condition: Stroke
- Condition: Secondary Prevention
- Intervention (Drug): optional ASA as comedication
- Intervention (Drug): placebo to ASA
- Intervention (Drug): placebo to optional ASA as comedication
- Intervention (Drug): placebo to dabigatran etexilate
- Intervention (Drug): ASA 100 mg
- Intervention (Drug): dabigatran etexilate
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source (`cardio:pubmed-31091372`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups (`cardio:pubmed-32404035`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS (`cardio:pubmed-33504190`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis (`cardio:pubmed-33588594`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial (`cardio:pubmed-34649459`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS Trial (`cardio:pubmed-35656979`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0d0c1dfbcc2377466dd53637d89a059207801b14ee0fe2ae074249445a84cbb2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
